IP Library Granted Patent US 8,859,722
Granted Patent B2
US 8,859,722 · App. 13/561,624 · Granted Oct 14, 2014

Hemolysin and its protein fragments in sero-detection of anaplasma phagocytophilum

Inventors: John G. Hoey (Framingham, MA); Denise P. Dimitrov (Hamilton, NJ); Lisa P. Huang (Princeton, NJ); Martin E. Adelson (East Windsor, NJ); Eli Mordechai (Robbinsville, NJ)
Assignee: Medical Diagnostic Laboratories, LLC
C07K14/29G01N2469/20G01N33/56911C07K14/195
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,859,722
App. No.
13/561,624
Granted
Oct 14, 2014
Kind
B2
Abstract

Disclosed is the cloning, expression and purification of a hemolysin protein and its protein fragments in Anaplasma phagocytophilum . The recombinant hemolysin and its protein fragments are useful in the ELISA detection of anaplasma pathogen. The use of same as a kit for ELISA is also disclosed.

Claims (31)

1. A composition comprising an isolated polypeptide and a support, wherein said isolated polypeptide is a recombinant polypeptide, consisting of the amino acid sequence selected from the group consisting of SEQ ID NO: 19, SEQ ID NO: 21, and SEQ ID NO: 23.

2. The composition of claim 1 , wherein said isolated recombinant polypeptide consists of the amino acid sequence set forth in SEQ ID NO: 19.

3. The composition of claim 1 , wherein said isolated recombinant polypeptide consists of the amino acid sequence set forth in SEQ ID NO: 21.

4. The composition of claim 1 , wherein said isolated recombinant polypeptide consists of the amino acid sequence set forth in SEQ ID NO: 23.

5. The composition of claim 1 , wherein said support is selected from the group consisting of polyethylene, polypropylene and glass.

6. The composition of claim 1 , wherein said support is a microtiter well.

7. The composition of claim 2 , wherein said isolated polypeptide is recombinantly expressed using an isolated polynucleotide, said isolated polynucleotide has a nucleotide sequence set forth in SEQ ID NO: 18.

8. The composition of claim 3 , wherein said isolated polypeptide is recombinantly expressed using an isolated polynucleotide, said isolated polynucleotide has a nucleotide sequence set forth in SEQ ID NO: 20.

9. The composition of claim 4 , wherein said isolated polypeptide is recombinantly expressed using an isolated polynucleotide, said isolated polynucleotide has a nucleotide sequence set forth in SEQ ID NO: 22.

10. A method of preparing the composition of claim 2 , comprising the steps of:

(i) introducing an isolated polynucleotide into a host cell, said isolated polynucleotide has a nucleotide sequence set forth in SEQ ID NO: 18;

(ii) growing said host cell in a culture under suitable conditions to permit production of said isolated polypeptide;

(iii) isolating said isolated polypeptide, and

(iv) providing a support, wherein, said composition is comprised of said isolated polypeptide and said support.

11. A method of preparing the composition of claim 3 , comprising the steps of:

(i) introducing an isolated polynucleotide into a host cell, said isolated polynucleotide has a nucleotide sequence set forth SEQ ID NO: 20;

(ii) growing said host cell in a culture under suitable conditions to permit production of said isolated polypeptide;

(iii) isolating said isolated polypeptide, and

(iv) providing a support, wherein, said composition is comprised of said isolated polypeptide and said support.

12. A method of preparing the composition of claim 4 , comprising the steps of:

(i) introducing an isolated polynucleotide into a host cell, said isolated polynucleotide has a nucleotide sequence set forth in SEQ ID NO: 22;

(ii) growing said host cell in a culture under suitable conditions to permit production of said isolated polypeptide; and

(iii) isolating said isolated polypeptide, and

(iv) providing a support, wherein, said composition is comprised of said isolated polypeptide and said support.

13. The composition of claim 1 , further comprising an isolated polypeptide and a support, wherein said isolated polypeptide is a recombinant polypeptide consisting of the amino acid sequence set forth in SEQ ID NO: 17.

14. The composition of claim 13 , wherein said support is selected from the group consisting of polyethylene, polypropylene and glass.

15. The composition of claim 13 , wherein said support is a microtiter well.

16. The composition of claim 13 , wherein said isolated polypeptide set forth in SEQ ID NO: 17 is produced by a method comprising the steps of:

(i) introducing an isolated polynucleotide into a host cell, said isolated polynucleotide has a nucleotide sequence set forth in SEQ ID NO: 16;

(ii) growing said host cell in a culture under suitable conditions to permit production of said isolated polypeptide; and

(iii) isolating said isolated polypeptide.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Jun 12, 2018
From: WELLS FARGO BANK, NATIONAL ASSOCIATION
To: MEDICAL DIAGNOSTIC LABORATORIES L. L. C.
Reel/Frame 046354/0817 →
SECURITY INTEREST Recorded Apr 27, 2018
From: MEDICAL DIAGNOSTIC LABORATORIES, L.L.C.
To: TD BANK, N.A.
Reel/Frame 046031/0381 →
SECURITY INTEREST Recorded Mar 1, 2016
From: MEDICAL DIAGNOTIC LABORATORIES, L.L.C.
To: WELLS FARGO BANK, NATIONAL ASSOCIATION
Reel/Frame 037963/0744 →
Continuity (3)
Division 12658537 · Feb 9, 2010
Provisional Application 61208876 · Feb 27, 2009
Related Publication 20130189715A1 · Jul 25, 2013